- GlobeNewswire•3 days ago
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment
SALT LAKE CITY and BOULDER, Colo., April 27, 2017-- Myriad Genetics, Inc. and Clovis Oncology, Inc. today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment ...
- Zacks•6 days ago
Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.
- GlobeNewswire•12 days ago
SALT LAKE CITY, April 18, 2017-- Myriad Genetics, Inc. today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on ...
MYGN : Summary for Myriad Genetics, Inc. - Yahoo Finance
Myriad Genetics, Inc. (MYGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||15.28 x 100|
|Ask||21.00 x 200|
|Day's Range||18.09 - 18.45|
|52 Week Range||15.15 - 36.71|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.78|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|